Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.53 |
| ▸ | RXRA | P19793 | 10/20 | 0.53 |
| ▸ | RARG | P13631 | 10/20 | 0.53 |
| ▸ | RXRB | P28702 | 8/20 | 0.53 |
| ▸ | RXRG | P48443 | 8/20 | 0.53 |
| ▸ | RARA | P10276 | 6/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10596854 | 0.75 | CYP1A2 (0.37) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL10643383 | 0.72 | TUBB1 (0.38) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL3688713 | 0.70 | RXRA (1.00) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL3688710 | 0.70 | RXRA (1.00) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL3688709 | 0.70 | RXRA (1.00) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL9067692 | 0.70 | RARA (0.65) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL9067691 | 0.70 | RARA (0.65) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL10990211 | 0.70 | RARA (0.65) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL28943223 | 0.69 | RXRA (0.54) | RARBRXRARARGRXRBRXRG | |
| SCHEMBL10937270 | 0.65 | RXRA (0.77) | RARBRXRARARGRXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-0688213-B1 | TREATMENT OF TUMORS WITH COMPOUNDS HAVING RXR RETINOID RECEPTOR AGONIST ACTIVITY | ALLERGAN INC (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1159961-A2 | Treatment of tumors with compounds having RxR retinoid receptor agonist activity | ALLERGAN, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-0909560-A2 | Treatment o tumors with compounds having RXR retinoid receptor agoinst activity | ALLERGAN, INC. (US) | 1999-04-21 | — | — | EP | disclosed |
| EP-0688213-A1 | TREATMENT OF TUMORS WITH COMPOUNDS HAVING RXR RETINOID RECEPTOR AGONIST ACTIVITY | ALLERGAN, INC. (US) | 1995-12-27 | — | — | EP | disclosed |
| US-5399586-A | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity | ALLERGAN, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1994020093-A1 | TREATMENT OF TUMORS WITH COMPOUNDS HAVING RXR RETINOID RECEPTOR AGONIST ACTIVITY | ALLERGAN, INC. (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |